PuSH - Publication Server of Helmholtz Zentrum München

Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors.

Int. J. Cancer 124, 2077-2081 (2009)
Open Access Green as soon as Postprint is submitted to ZB.
Overexpression of the human epidermal growth factor receptor 2 (HER2) in breast tumors is associated with bad prognosis. Therefore, it is highly relevant to further improve understanding of the regulatory mechanisms of HER2 expression. In addition to gene amplification, transcriptional regulation plays a crucial role in HER2 overexpression. In this study, we analyzed 3 polymorphisms E2F2_-5368-A>G, CCND1-870-A>G and CCND3_-677_C>T located in genes involved in cell cycle regulation in the GENICA population-based and age-matched breast cancer case-control study from Germany. We genotyped 1,021 cases and 1,015 controls by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Statistical analyses were performed by conditional logistic regression. We observed no differences in genotype frequencies between breast cancer cases and controls. Subgroup analysis showed associations between carriers of the E2F2_-5368_G allele (OR: 0.60, 95% CI: 0.42-0.85), carriers of the (C) over bar CND (1) over bar _870 G allele (OR: 0.66, 95% CI: 0.45-0.96) and carriers of the -CC (N) over bar D3_-677_T allele (OR: 1.72, 95% CI: 1.20-2.49) and HER2 expression in breast tumors. This finding points to an association of an increased expression of these cell cycle regulators with lower expression of HER2. An explanation for this observation might be that low expression of E2F2, CCND1 and CCND3 decrease levels of factors down-regulating HER2. We conclude that the analyzed polymorphisms located in E2F2, CCND1 and CCAID3 are potential markers for HER2 status of breast tumors.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords E2F2; CCND1; CCND3; polymorphism; breast tumor; HER2 status; single-nucleotide polymorphisms; cancer risk; cyclin d1; transcription factor; cell-cycle; adjuvant chemotherapy; gene; overexpression; trastuzumab; expression
Reviewing status